Details of the Drug Combination

General Information of Drug Combination (ID: DC16REB)

Drug Combination Name
Omaveloxolone Moxifloxacin
Indication
Disease Entry Status REF
Health Adult Subjects Phase 1 [1]
Component Drugs Omaveloxolone   DMLMNFX Moxifloxacin   DMU8V4S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Omaveloxolone
Disease Entry ICD 11 Status REF
Friedreich's ataxia 8A03.10 Approved [2]
Melanoma 2C30 Phase 1/2 [3]
Psychiatric disorder 6E8Z Clinical trial [4]
Omaveloxolone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Nuclear factor erythroid 2-related factor 2 (Nrf2) TTA6ZN2 NF2L2_HUMAN Activator [3]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [5]
Mycoplasma pneumoniae pneumonia N.A. Approved [6]
Peritonitis N.A. Approved [6]
Pneumonic plague N.A. Approved [6]
Septicemic plague N.A. Approved [6]
Staphylococcal pneumonia N.A. Approved [6]
Staphylococcus aureus infection N.A. Approved [6]
Streptococcal pneumonia N.A. Approved [6]
Tuberculosis 1B10-1B14 Approved [6]
Pneumonia caused by chlamydia N.A. Investigative [6]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [6]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [7]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05927649) A TQTc Study for Omaveloxolone
2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216718.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res. 2014 Jul;306(5):447-54.
5 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
6 Moxifloxacin FDA Label
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.